Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Komrokji

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Blood|April 2, 2014
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJeffrey E Lancet, Jorge E Cortes, Donna E Hogge, et al.
Leukemia|February 25, 2025
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasmNadia Gharaee, Joanna Wegrzyn-Woltosz, Jihong Jiang, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
Blood Cancer Journal|February 2, 2022
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patientsAbhishek A Mangaonkar, Terra L Lasho, Rhett P Ketterling, et al.
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
Annals of Hematology|July 2, 2026
Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024)Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2023
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene FusionYumeng Zhang, Lynn Nguyen, Chuanyi M Lu, et al.
Leukemia|July 21, 2018
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMMLSandrine Niyongere, Nolwenn Lucas, Jun-Min Zhou, et al.
Advances in Hematology|November 24, 2025
Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer CentersConnor Willis, Andre Hejazi, Vonetta L Williams, et al.
Iscience|September 26, 2022
A machine learning model of response to hypomethylating agents in myelodysplastic syndromesNathan Radakovich, David A Sallman, Rena Buckstein, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Blood|April 2, 2014
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJeffrey E Lancet, Jorge E Cortes, Donna E Hogge, et al.
Leukemia|February 25, 2025
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasmNadia Gharaee, Joanna Wegrzyn-Woltosz, Jihong Jiang, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
Blood Cancer Journal|February 2, 2022
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patientsAbhishek A Mangaonkar, Terra L Lasho, Rhett P Ketterling, et al.
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
Annals of Hematology|July 2, 2026
Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024)Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2023
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene FusionYumeng Zhang, Lynn Nguyen, Chuanyi M Lu, et al.
Leukemia|July 21, 2018
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMMLSandrine Niyongere, Nolwenn Lucas, Jun-Min Zhou, et al.
Advances in Hematology|November 24, 2025
Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer CentersConnor Willis, Andre Hejazi, Vonetta L Williams, et al.
Iscience|September 26, 2022
A machine learning model of response to hypomethylating agents in myelodysplastic syndromesNathan Radakovich, David A Sallman, Rena Buckstein, et al.
Pageof 13